D. Boral Capital Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $31.00 target price on the stock.

NRXP has been the topic of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Thursday, March 20th. BTIG Research began coverage on NRx Pharmaceuticals in a research report on Wednesday, April 2nd. They set a "buy" rating and a $18.00 price target on the stock. Ascendiant Capital Markets boosted their price objective on NRx Pharmaceuticals from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Finally, Wall Street Zen upgraded shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $28.50.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP traded down $0.16 on Friday, reaching $3.10. 318,234 shares of the company's stock traded hands, compared to its average volume of 415,312. The stock has a market cap of $53.60 million, a PE ratio of -1.54 and a beta of 1.54. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $6.01. The stock has a 50-day simple moving average of $2.53 and a 200 day simple moving average of $2.48.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06. The business had revenue of $1.14 million during the quarter, compared to analysts' expectations of $1.14 million. As a group, analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals during the 4th quarter valued at $56,000. Millennium Management LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at about $61,000. Sassicaia Capital Advisers LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at about $33,000. Anson Funds Management LP raised its stake in NRx Pharmaceuticals by 30.3% in the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company's stock worth $408,000 after buying an additional 43,135 shares in the last quarter. Finally, AdvisorShares Investments LLC lifted its holdings in NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock worth $683,000 after buying an additional 180,229 shares during the period. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.